Juno Therapeutics (JUNO) Misses Q4 EPS by 6c

Juno Therapeutics (NASDAQ: JUNO) reported Q4 EPS of ($0.53), $0.06 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $4.15 million versus the consensus estimate of $4.79 million.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities